POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride (KCl) dissociation yields potassium ions that maintain intracellular fluid volume, transmembrane electrochemical gradients, and action potentials in excitable tissues. It repletes potassium deficits and prevents hypokalemia. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid osmolality and volume.
| Metabolism | Potassium is not metabolized; it is primarily excreted renally. Sodium and chloride are also not metabolized; they are excreted mainly by the kidneys. |
| Excretion | Renal: >90% as potassium ion; negligible biliary/fecal excretion under normal conditions. |
| Half-life | Not applicable as a drug; potassium homeostasis is tightly regulated. Serum potassium has a distribution half-life of ~1-1.5 h, with renal elimination half-life depending on glomerular filtration and tubular secretion, typically 6-8 h in normal renal function. |
| Protein binding | Negligible; potassium is freely ionized and not significantly protein-bound. |
| Volume of Distribution | Approximately 0.5 L/kg (total body water); primarily extracellular, with intracellular distribution regulated by Na+/K+ ATPase. |
| Bioavailability | IV: 100%. Not administered orally in this formulation. |
| Onset of Action | IV infusion: Immediate (within minutes) as potassium is directly administered into the bloodstream. |
| Duration of Action | Duration depends on infusion rate and renal function; a single dose effect lasts until potassium is redistributed and excreted. Continuous infusion maintains steady state. |
| Molecular Weight | 74.55 |
Intravenous infusion. Adult dose: 10-20 mEq/hour of potassium chloride, typically administered in a concentration of 0.22% (which is 2 mEq/100 mL) in 0.9% sodium chloride. Rate should not exceed 10 mEq/hour for non-emergency situations; maximum daily dose is 200 mEq.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-60 mL/min: reduce dose by 25-50% and monitor potassium levels closely. GFR <30 mL/min: avoid use or use with extreme caution, reduce dose by at least 50% and frequent monitoring. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. However, monitor serum potassium levels regularly. In severe hepatic impairment (Child-Pugh class C), consider potential reduced drug clearance and monitor electrolytes more frequently. |
| Pediatric use | Weight-based intravenous infusion: 0.5-1 mEq/kg/dose, maximum single dose 2 mEq/kg, to be infused at a rate not exceeding 0.5 mEq/kg/hour. Dilute to a maximum concentration of 0.22% (2 mEq/100 mL) in 0.9% sodium chloride. |
| Geriatric use | Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 5-10 mEq/hour) and titrate based on serum potassium levels. Monitor renal function and electrolyte levels frequently. |
| 1st trimester | Potassium chloride is essential for maternal and fetal physiology. No known teratogenicity; use only if clearly needed. Hypokalemia should be corrected cautiously to avoid hyperkalemia. |
| 2nd trimester | Similar to t1: indicated for correction of hypokalemia. Monitor serum potassium closely due to altered renal function in pregnancy. |
| 3rd trimester | May be used for hypokalemia. Risk of hyperkalemia in mother and fetus if excessive; avoid in preeclampsia or renal impairment. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium readily crosses the placenta via active transport and diffusion. Fetal serum potassium is maintained slightly higher than maternal. Excessive maternal hyperkalemia can affect fetal cardiac function. |
| Breastfeeding | Potassium is a normal constituent of breast milk. Supplemental potassium from IV infusion may increase milk levels but not clinically significant. No adverse effects reported in infants. Use caution in mothers with renal impairment or on potassium-sparing diuretics. |
| Lactation Rating | L1: Compatible |
| Teratogenic Risk | Potassium chloride and sodium chloride are physiological ions and not teratogenic. No fetal risk at therapeutic doses. Trimester-specific risks: None. |
| Fetal Monitoring | Monitor serum electrolytes, renal function, and fluid status. Assess for signs of hyperkalemia (ECG changes) and hypernatremia. Fetal monitoring not routinely required. |
| Fertility Effects | No known effects on fertility. |
■ FDA Black Box Warning
Concentrated potassium chloride injection (not applicable to this dilute solution) has a black box warning for fatal cardiac arrhythmias if given undiluted. For 0.22% KCl in 0.9% NaCl, no specific black box warning exists; however, the risk of hyperkalemia necessitates careful monitoring.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment with oliguria or anuriaAddison's diseaseAcute dehydrationConcurrent use of potassium-sparing diureticsHyperchloremia (relative, for chloride component)
| Precautions | Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia. Monitor serum potassium, sodium, and chloride levels, and ECG. Avoid rapid infusion. Risk of hyperkalemia may be increased with potassium-sparing diuretics, ACE inhibitors, or ARBs. Do not use in patients with oliguria, anuria, or untreated Addison's disease. |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes, tomatoes, nuts, beans) and potassium-containing salt substitutes during treatment, as this may increase risk of hyperkalemia. |
| Clinical Pearls | This solution is typically used for maintenance fluid therapy and mild hypokalemia in patients with concurrent sodium depletion. Infusion rate should not exceed 10-20 mEq/h of potassium to avoid hyperkalemia; cardiac monitoring is advised at rates >10 mEq/h. Avoid use in severe renal impairment (CrCl <30 mL/min) or hyperkalemia. Contains 2 mEq/L of potassium, which provides approximately 0.22% KCl. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics. |
| Patient Advice | This intravenous fluid contains potassium; inform your doctor if you have kidney problems or are on medications that affect potassium levels. · Report any signs of hyperkalemia such as muscle weakness, irregular heartbeat, or tingling in the hands/feet. · Do not consume potassium-rich foods or supplements unless directed by your doctor. · The fluid is for intravenous use only and will be administered by a healthcare professional. |
Loading safety data…